Structure of the Bcr-Abl oncoprotein oligomerization domain
about
ABL tyrosine kinases: evolution of function, regulation, and specificityNew Developments in Chronic Myeloid Leukemia: Implications for TherapyA systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemiaA Src-like inactive conformation in the abl tyrosine kinase domainDifferences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia.The KRAB-associated co-repressor KAP-1 is a coiled-coil binding partner, substrate and activator of the c-Fes protein tyrosine kinase.Intrinsic structural disorder confers cellular viability on oncogenic fusion proteinsBcr is a substrate for Transglutaminase 2 cross-linking activity.Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.Re-engineered p53 chimera with enhanced homo-oligomerization that maintains tumor suppressor activity.Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity.Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasmsDisruption of Bcr-Abl coiled coil oligomerization by design.Pegasus: a comprehensive annotation and prediction tool for detection of driver gene fusions in cancer.A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemiaStructure, regulation, signaling, and targeting of abl kinases in cancer.Structure and dynamic regulation of Abl kinases.Orientation and oligomerization specificity of the Bcr coiled-coil oligomerization domain.Applying the discovery of the Philadelphia chromosome.Molecular biology of bcr-abl1-positive chronic myeloid leukemia.One reporter for in-cell activity profiling of majority of protein kinase oncogenes.Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.Development of an effective therapy for chronic myelogenous leukemiaStructural Basis of TPR-Mediated Oligomerization and Activation of Oncogenic Fusion Kinases.BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifsImproved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis.Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML.Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis.Heterogeneity of BCR-ABL rearrangement in patients with chronic myeloid leukemia in Pakistan.Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization.Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase.Design of coiled-coil protein-origami cages that self-assemble in vitro and in vivo.Molecular processes involved in B cell acute lymphoblastic leukaemia.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.
P2860
Q24299738-97B2072B-BEBC-4D0D-AC29-D95BE7DB31F3Q26745669-D1A5E9D4-6FFC-4D2E-8C5C-FE7CABF803ABQ28387697-13F932A0-C7BB-452E-B94D-D2015CB238F1Q28469170-A269437C-494D-4B9E-A768-C6621039758CQ30009436-F189CF10-883D-4BC8-8C60-DA6CC6117E5DQ33247592-B860337E-F160-4E6A-8802-89BFC63F79CFQ33514873-2508FF70-60A8-41D7-BB93-03554A900C8BQ33817561-58DEBBB0-7ABD-45DF-AC7D-183F40AAC00DQ33828334-0E399AC2-2354-4A03-B719-09792F191634Q33966877-B63AFAB8-B91C-4D12-8927-91E478EBD72CQ34181347-D651E537-8C53-4FF5-B12E-A0669B0DF122Q35127960-5D852A77-3069-4C92-9590-381498E4F3B2Q35145034-27BEA77F-126F-4380-BDD8-2B2B511EE62CQ35237184-FED9E923-3CA8-49C7-97BB-1FC0D5C0175DQ36210636-BA58580A-0EBB-4B61-B946-5B3BB7D9F80AQ36443429-1CDAD284-8FB2-424F-BA4A-A4AF86CC1EBDQ36635994-BFF27CAC-F417-479F-BE48-E2203AE70503Q36853551-6E869A09-D1F2-48CD-B8CC-1534F93DC766Q36900109-5E1E0D3C-16D1-4FD9-AFF3-6DCC35886352Q37283128-7C79E08C-AAB5-4161-AA9D-0FB9F3CF3893Q37643703-A263759D-47C0-4750-AECE-856F5A82793BQ37919976-0227F6F7-5E9A-498D-BADB-AA2088942A25Q37966917-2EB488A8-31EA-44EC-8676-6DEF7DFF7619Q38431115-D97B9344-1C02-4419-A417-D80124C9341CQ39541093-DB6D1099-CA1B-485E-B2D4-B1853B1CBA64Q39674045-C11D26EE-6D90-47C1-89BE-F3D2DB66B749Q41948387-F18F6BD4-C901-45B6-A3C3-8FC5B6731A94Q41974410-84D07A1E-AF6E-4042-AD84-F00A7C8FF063Q42195178-DECDEF35-5601-4049-8794-1D336B8A5612Q42768987-55896EBF-77BD-46A3-AE69-0B5C96BA88A1Q46856578-801C6FF9-57E1-4564-A6B3-A34F99520E1AQ47093610-2E6CDFDA-0A54-4860-AAE8-475041569AA3Q47441562-92400678-259B-404F-93F1-CB64A3D86799Q48218289-AB403E11-052B-44EC-B0E9-E9A55E222229Q48263612-F8E65808-C091-4052-9E9B-7B6C5303B8F2
P2860
Structure of the Bcr-Abl oncoprotein oligomerization domain
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Structure of the Bcr-Abl oncoprotein oligomerization domain
@ast
Structure of the Bcr-Abl oncoprotein oligomerization domain
@en
Structure of the Bcr-Abl oncoprotein oligomerization domain
@nl
type
label
Structure of the Bcr-Abl oncoprotein oligomerization domain
@ast
Structure of the Bcr-Abl oncoprotein oligomerization domain
@en
Structure of the Bcr-Abl oncoprotein oligomerization domain
@nl
prefLabel
Structure of the Bcr-Abl oncoprotein oligomerization domain
@ast
Structure of the Bcr-Abl oncoprotein oligomerization domain
@en
Structure of the Bcr-Abl oncoprotein oligomerization domain
@nl
P2093
P356
P1476
Structure of the Bcr-Abl oncoprotein oligomerization domain
@en
P2093
Peter S Kim
Saghi Ghaffari
P304
P356
10.1038/NSB747
P407
P577
2002-02-01T00:00:00Z